text: Exercise or conversion by Joel Kanter of 1250 shares of WaferGen Bio subject to Rule 16b 3 | WGBS - Macroaxis
  Exercise or conversion by Joel Kanter of 1250 shares of WaferGen Bio subject to Rule 16b-3
  WaferGen Bio systems Inc insider trading alert for exercise of restricted stock units by Joel Kanter, the corporate stakeholder, on October 2, 2017. This event was filed by Wafergen Biosystems Inc with SEC on 2010-12-20. Statement of changes in beneficial ownership - SEC Form 4
  WaferGen Bio is currently under evaluation in price to book category among related companies. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.
  IIVI 2.51 %
  COHR 1.31 %
  ORBK 1.18 %
  IART 0.43 %
  MKSI 0.30 %
  ABAX 0.01 %
  FTV 0.03 %
  CGNX 0.18 %
  BRKR 1.56 %
  See also WaferGen Bio Hype Analysis, WaferGen Bio Correlation and WaferGen Bio Performance. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.